Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an update.
Recce Pharmaceuticals has notified the market of the cessation of 66,667 RCEAO options, which were due to expire on 7 November 2029 with an exercise price of $0.56. The options have lapsed because the conditional rights attached to them were not satisfied or became incapable of being satisfied, resulting in a modest reduction in the company’s potential future share dilution and a minor adjustment to its issued capital profile.
The lapse of these options has no immediate cash impact but slightly streamlines Recce’s capital structure, which may be viewed positively by existing shareholders concerned about overhang from unexercised securities. The announcement underscores the conditional nature of certain incentive or performance-related instruments in the company’s financing mix and signals that specific milestones or conditions tied to these options were not achieved by the February 25, 2026 cut-off date.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australian biotechnology company listed on the ASX under the code RCE. It operates in the pharmaceuticals sector, focusing on the development of therapeutic products, with its capital structure including various classes of options and securities traded on the Australian market.
Average Trading Volume: 101,513
Technical Sentiment Signal: Hold
Current Market Cap: A$143.1M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.